Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Third Quarter 2014 Financial Results

      - Solid third quarter results reported and strong fourth quarter expected -

      - Full year 2014 Adjusted income from continuing operations per share guidance increased -

      - Conference call at 8:30 a.m. ET on October 30, 2014 -


      News provided by

      Cambrex Corporation

      Oct 30, 2014, 07:00 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Oct. 30, 2014 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2014.

      Highlights

      • Third quarter sales increased 4.0% to $81.1 million from $78.0 million in the same period last year.
      • Third quarter EBITDA increased 6.5% to $18.1 million compared to $17.0 million in the same period last year (see table at the end of this release).   
      • Debt, net of cash, improved $21.1 million during the third quarter to $33.5 million.
      • Company continues to expect full year 2014 sales, excluding the impact of foreign currency, to grow between 13% and 16% from 2013, and full year EBITDA to be between $74 and $78 million.   Adjusted income from continuing operations is now expected to be between $1.11 and $1.19 per share, a $0.04 increase at both the low and high ends of the range (see Financial Expectations – Continuing Operations section below).

      "We continue to be very pleased with the positive trends in our business and expect a very strong fourth quarter," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.  "During the third quarter, we added two new late stage clinical products to our portfolio and two of our customers' products in that portfolio were approved for commercial sale.  Demand across all of our product categories remains strong, particularly in custom manufacturing and controlled substances.  Utilization of our large scale assets in both the U.S. and Europe continues to grow as pharmaceutical customers increasingly seek out high quality manufacturers like Cambrex.  Our current view suggests we will maintain our positive momentum with strong expected growth in 2015."

      Basis of Reporting

      The Company has provided a reconciliation of GAAP amounts to adjusted (i.e. Non-GAAP) amounts at the end of this press release.  Management believes that the adjusted amounts provide useful information to investors due to the magnitude and nature of certain expenses recorded in the GAAP amounts.

      Third Quarter 2014 Operating Results – Continuing Operations

      Sales were $81.1 million for the quarter, compared to $78.0 million in the same period last year, representing a 4.0% increase, including the unfavorable impact of foreign exchange of 1.0%.  The Company recorded sales increases in most of its product categories, with strong growth in certain branded APIs and controlled substances.  Pricing was flat compared to the third quarter last year.

      Gross margins increased to 35.0% from 32.0% compared to the same period last year.  This increase was primarily due to a favorable mix of products, proceeds from an insurance settlement, improved production efficiencies and a favorable currency impact.

      Selling, general and administrative expenses were $12.5 million compared to $11.1 million in the same period last year.  The increase was mainly due to higher personnel expenses.

      Research and development expenses were $3.8 million compared to $2.6 million in the same period last year.  The increase was primarily the result of increased personnel costs required to develop an increased number of products in the R&D pipeline.

      Operating profit increased to $12.0 million from $11.3 million in the same period last year.  The increase in operating profit was primarily the result of higher gross profit partially offset by higher operating expenses.  EBITDA was $18.1 million compared to $17.0 million in the same period last year. 

      The provision for income taxes was $2.5 million and included a benefit of $0.8 million for a partial reversal of a valuation allowance against certain U.S. tax assets.  Excluding the impact of this benefit, the effective tax rate would have been 29.4% during the quarter compared to 37.7% in the same period last year.

      Income from continuing operations was $8.9 million or $0.28 per share compared to $6.3 million or $0.20 per share in the same period last year.  Adjusted income from continuing operations was $8.8 million or $0.28 per share, compared to $7.1 million or $0.23 per share, respectively, in the same period last year (see table at the end of this release).

      Capital expenditures and depreciation were $7.2 million and $5.9 million, respectively, compared to $6.2 million and $5.7 million, respectively, in the same period last year. 

      Financial Expectations – Continuing Operations

      The following table shows the Company's current expectations for its full year 2014 financial performance versus its expectations from the previous quarter.



      Current
      Expectations


      Previous
      Expectations






      Gross sales increase


      13% - 16%


      13% - 16%






      Adjusted EBITDA


      $74 - $78 million


      $74 - $78 million






      Adjusted income from continuing
      operations per share


      $1.11 - $1.19


      $1.07 - $1.15






      Reduction of debt, net of cash


      $25 - $30 million


      $25 - $30 million






      Capital expenditures


      $35 - $39 million


      $35 - $39 million






      Depreciation


      $24 - $25 million


      $25 - $27 million






      Effective tax rate


      33% - 36%


      33% - 36%

      Consistent with prior guidance for the full year 2014, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, restructuring activities and outcomes of tax disputes and do not reflect Zenara's results.  Sales expectations exclude the impact of foreign currency.  Adjusted EBITDA and Adjusted income from continuing operations per share are computed on a basis consistent with the reconciliation of the year to date results in the tables at the end of this release.

      The Company increased its guidance for full year 2014 Adjusted income from continuing operations by $0.04 per share at both the low and high ends of the range due to lower estimates of depreciation and interest expense for 2014.  Depreciation was adjusted downward due to later than expected timing of certain assets being placed in service and foreign currency impact.  Interest expense was adjusted downward due to lower than expected interest rates.

      We expect Zenara to generate low to mid single digit millions in revenues and a small EBITDA loss in 2014.  As previously announced, the Company purchased all previously unowned shares in Zenara Pharma and as such, has consolidated Zenara's results from the purchase date of May 23, 2014 in its 2014 results. The Company's EBITDA expectations for Zenara do not include a loss of $4.1 million recorded in the second quarter of 2014 related to the purchase of the previously unowned shares of Zenara.

      The Company expects to reduce the valuation allowance against certain U.S. tax assets by approximately $17.2 million for the full year 2014, which would reduce tax expense accordingly. The valuation allowance released for the third quarter and year to date periods was $0.8 million and $15.2 million, respectively.  The actual amount of the reduction in the valuation allowance may be higher or lower depending on the amount and type of U.S. income during the rest of the year. The full year effective tax rate included in the table above excludes this benefit and the impact of the purchase of the remaining Zenara shares.  The Company expects to pay only a small amount of cash taxes in the U.S. during the year. The tax rate and amount of cash taxes paid will be sensitive to the geographic mix of income, and quarterly effective tax rates may be volatile. 

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's third quarter 2014 Form 10-Q is filed with the SEC.

      Conference Call and Webcast

      A conference call to discuss the Company's third quarter 2014 results will begin at 8:30 a.m. Eastern Time on Thursday, October 30, 2014 and can be accessed by calling 1-800-505-9568 for domestic and +1-416-204-9271 for international.  Please use the passcode 6387777 and call approximately 10 minutes prior to the start time.  A webcast will be available in the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Thursday, November 6, 2014 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the passcode 6387777 to access the replay. 

      About Cambrex

      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.    

      Forward Looking Statements

      This document contains "forward-looking statements," including statements or tables regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," and those attributed to our President and Chief Executive Officer in this document.  These and other forward looking statements may be identified by the fact that they use words such as "guidance," "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2013, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of our customers' products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, changes in foreign exchange rates, uncollectible receivables, the timing of orders and the Company's ability to meet its production plan and its customer delivery schedules, particularly during the fourth quarter of 2014, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products and continued demand in the U.S. for late stage clinical products or the successful outcome of the Company's investment in new products.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

      Use of Non-GAAP Financial Measures

      EBITDA and Adjusted Income from Continuing Operations are non-GAAP financial measures.  The Company defines EBITDA as operating profit plus depreciation and amortization expense and Adjusted Income from Continuing Operations is calculated in a manner consistent with that shown in the tables at the end of this release.   Other companies may have a different definition of EBITDA and Adjusted Income from Continuing Operations, therefore, these measures may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA and Adjusted Income from Continuing Operations should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA and Adjusted Income from Continuing Operations among several other metrics to assess and analyze its operational results and trends.  Cambrex also believes EBITDA and Adjusted Income from Continuing Operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended September 30, 2014 and 2013

      (in thousands, except per-share data)













      2014



      2013





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      81,145




      $

      77,992



           Commissions, Allowances and Rebates


      504





      547



      Net Sales


      80,641





      77,445













           Other Revenue


      659





      7













      Net Revenues


      81,300





      77,452













           Cost of Goods Sold


      52,894


      65.2%



      52,486


      67.3%











      Gross Profit


      28,406


      35.0%



      24,966


      32.0%











      Operating Expenses










           Selling, General and Administrative Expenses


      12,541


      15.5%



      11,128


      14.3%

           Research and Development Expenses


      3,839


      4.7%



      2,588


      3.3%

      Total Operating Expenses


      16,380


      20.2%



      13,716


      17.6%











      Operating Profit


      12,026


      14.8%



      11,250


      14.4%











      Other Expenses:










           Interest Expense, Net


      570





      664



           Equity in Losses of Partially-Owned Affiliates


      -





      508



           Other Expenses, Net


      37





      5













      Income Before Income Taxes


      11,419


      14.1%



      10,073


      12.9%











           Provision for Income Taxes


      2,537





      3,799













      Income from Continuing Operations

      $

      8,882


      10.9%


      $

      6,274


      8.0%











      Loss from Discontinued Operations, Net of Tax


      (113)





      (2,700)













      Net Income

      $

      8,769


      10.8%


      $

      3,574


      4.6%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.29




      $

      0.21



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)




      $

      (0.09)



         Net Income

      $

      0.28




      $

      0.12













      Diluted Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.28




      $

      0.20



         Loss from Discontinued Operations, Net of Tax

      $

      (0.00)




      $

      (0.08)



         Net Income

      $

      0.28




      $

      0.12













      Weighted Average Shares Outstanding










           Basic


      30,801





      30,184



           Diluted


      31,599





      31,052



      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Nine Months Ended September 30, 2014 and 2013

      (in thousands, except per-share data)













      2014



      2013





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      245,309




      $

      214,201



           Commissions, Allowances and Rebates


      1,678





      775



      Net Sales


      243,631





      213,426













           Other Revenue


      1,667





      1,714













      Net Revenues


      245,298





      215,140













           Cost of Goods Sold


      166,899


      68.0%



      146,174


      68.2%











      Gross Profit


      78,399


      32.0%



      68,966


      32.2%











      Operating Expenses










           Selling, General and Administrative Expenses


      38,734


      15.8%



      32,854


      15.3%

           Research and Development Expenses


      9,945


      4.1%



      7,547


      3.5%

      Total Operating Expenses


      48,679


      19.8%



      40,401


      18.9%











           Gain on Sale of Office Building


      -


      0.0%



      4,680


      2.2%











      Operating Profit


      29,720


      12.1%



      33,245


      15.5%











      Other Expenses:










           Interest Expense, Net


      1,635





      1,647



           Equity in Losses of Partially-Owned Affiliates


      4,618





      1,657



           Other Expenses, Net


      16





      11













      Income Before Income Taxes


      23,451


      9.6%



      29,930


      14.0%











           (Benefit)/Provision for Income Taxes


      (6,424)





      9,095













      Income from Continuing Operations

      $

      29,875


      12.2%


      $

      20,835


      9.7%











      Loss from Discontinued Operations, Net of Tax


      (457)





      (3,819)













      Net Income

      $

      29,418


      12.0%


      $

      17,016


      7.9%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.97




      $

      0.69



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)




      $

      (0.12)



         Net Income

      $

      0.96




      $

      0.57













      Diluted Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.95




      $

      0.67



         Loss from Discontinued Operations, Net of Tax

      $

      (0.02)




      $

      (0.12)



         Net Income

      $

      0.93




      $

      0.55













      Weighted Average Shares Outstanding










           Basic


      30,665





      30,081



           Diluted


      31,486





      30,938



      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of September 30, 2014 and December 31, 2013

      (in thousands)















      September 30,



      December 31,

      Assets


      2014



      2013







      Cash and Cash Equivalents

      $

      26,505


      $

      22,745

      Trade Receivables, Net


      45,642



      71,276

      Other Receivables


      11,873



      12,943

      Inventories, Net


      101,405



      89,965

      Prepaid Expenses and Other Current Assets


      8,977



      5,631

        Total Current Assets


      194,402



      202,560







      Property, Plant and Equipment, Net


      162,269



      171,966

      Goodwill


      45,108



      38,670

      Intangible Assets, Net


      8,908



      4,011

      Investments in and Advances to Partially-Owned Affiliates


      788



      13,364

      Deferred Income Taxes


      27,830



      19,799

      Other Non-Current Assets


      5,027



      7,667







        Total Assets

      $

      444,332


      $

      458,037







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      34,004


      $

      29,052

      Deferred Revenue


      11,787



      20,121

      Accrued Expenses and Other Current Liabilities


      43,510



      48,098

        Total Current Liabilities


      89,301



      97,271







      Long-Term Debt


      60,000



      79,250

      Deferred Income Taxes


      11,533



      12,835

      Accrued Pension Benefits


      34,634



      40,123

      Other Non-Current Liabilities


      16,459



      18,338







        Total Liabilities

      $

      211,927


      $

      247,817







        Stockholders' Equity

      $

      232,405


      $

      210,220







        Total Liabilities and Stockholders' Equity

      $

      444,332


      $

      458,037

      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Nine Months Ended September 30, 2014 and 2013

      (in thousands)









      Third Quarter 2014



      Third Quarter 2013








      Operating Profit

      $

      12,026



      $

      11,250








      Depreciation and Amortization


      6,066




      5,745








      EBITDA

      $

      18,092



      $

      16,995























      Nine Months 2014



      Nine Months 2013








      Operating Profit

      $

      29,720



      $

      33,245








      Gain on Sale of Office Building


      -




      (4,680)








      Adjusted Operating Profit


      29,720




      28,565








      Depreciation and Amortization


      17,915




      16,631








      Adjusted EBITDA

      $

      47,635



      $

      45,196

      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Nine Months Ended September 30, 2014 and 2013

      (in thousands)


















      Third Quarter 2014


      Third Quarter 2013








      Diluted
      EPS





      Diluted
      EPS

      Income from Continuing Operations

      $

      8,882

      $

      0.28


      $

      6,274

      $

      0.20














      Stock-Based Compensation, Net of Tax1


      609


      0.02



      573


      0.02

      Amortization of Purchased Intangibles


      182


      0.01



      270


      0.01

      Release of Valuation Allowance


      (824)


      (0.03)



      -


      -














      Adjusted Income from Continuing Operations

      $

      8,849

      $

      0.28


      $

      7,117

      $

      0.23












































      Nine Months 2014


      Nine Months 2013








      Diluted
      EPS





      Diluted
      EPS

      Income from Continuing Operations

      $

      29,875

      $

      0.95


      $

      20,835

      $

      0.67














      Stock-Based Compensation, Net of Tax1


      2,273


      0.07



      1,940


      0.06

      Loss on Acquisition of Zenara Shares


      4,122


      0.13



      -


      -

      Gain on Sale of Office Building, Net of Tax


      -


      -



      (3,173)


      (0.10)

      Amortization of Purchased Intangibles


      687


      0.02



      873


      0.03

      Release of Valuation Allowance


      (15,183)


      (0.48)



      -


      -

      Changes in Tax Laws


      -


      -



      (1,271)


      (0.04)














      Adjusted Income from Continuing Operations

      $

      21,774

      $

      0.69


      $

      19,204

      $

      0.62



























      1   Tax rate estimated at 35% for stock-based compensation.

      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.